Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glucagon-Like Peptide-1 Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT03889496
What this trial is testing

Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

Who this might be right for
Diabetes Mellitus
Radboud University Medical Center 12
Post-approval studies (Phase 4)Study completedNCT02686177
What this trial is testing

Effect of GLP-1 on Angiogenesis

Who this might be right for
Type 2 Diabetes
Assistance Publique - Hôpitaux de Paris 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT07431086
What this trial is testing

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Who this might be right for
Overweight or Obesity
Regeneron Pharmaceuticals 120
Very early researchActive Not RecruitingNCT06807970
What this trial is testing

Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist

Who this might be right for
Osteoarthritis (OA) of the Knee
The University of Hong Kong 54
Not applicableStudy completedNCT04295005
What this trial is testing

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 24,500
Early research (Phase 1)UnknownNCT02971722
What this trial is testing

JY09 in Chinese Healthy Subjects

Who this might be right for
Healthy
Beijing Dongfang Biotech Co., Ltd. 26
Not applicableLooking for participantsNCT07653412
What this trial is testing

Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

Who this might be right for
Obesity (Disorder)Anti-obesity AgentsPrecision Medicine
National and Kapodistrian University of Athens 220
Large-scale testing (Phase 3)Not Yet RecruitingNCT07668336
What this trial is testing

Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Eli Lilly and Company 170
Post-approval studies (Phase 4)Study completedNCT01744236
What this trial is testing

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Who this might be right for
Type 2 Diabetes
Amsterdam UMC, location VUmc 70
Post-approval studies (Phase 4)Study completedNCT04196231
What this trial is testing

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Who this might be right for
Type 2 Diabetes
University of Campania Luigi Vanvitelli 258
Not applicableWithdrawnNCT06759740
What this trial is testing

An Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients with Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas

Who this might be right for
Hypoglycaemia
The Affiliated Hospital Of Southwest Medical University
Not applicableUnknownNCT02118376
What this trial is testing

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

Who this might be right for
Obesity
Shanghai 10th People's Hospital 20
Large-scale testing (Phase 3)Looking for participantsNCT06825182
What this trial is testing

Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University 1,000
Post-approval studies (Phase 4)Study completedNCT04881110
What this trial is testing

Liraglutide and Peripheral Artery Disease

Who this might be right for
Type 2 DiabetesPeripheral Arterial Disease
University of Campania Luigi Vanvitelli 60
Not applicableLooking for participantsNCT07740291
What this trial is testing

Tirzepatide Impact Assessment Study

Who this might be right for
Obesity & OverweightCardiometabolic Health IndicatorsAddiction+2 more
Texas Tech University 27
Not applicableActive Not RecruitingNCT07115069
What this trial is testing

Comparison of Body Composition Changes With Weight Loss Interventions

Who this might be right for
Obesity
Vanderbilt University Medical Center 60
Post-approval studies (Phase 4)Looking for participantsNCT06324461
What this trial is testing

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

Who this might be right for
Myocardial Injury
The University of Hong Kong 372
Early research (Phase 1)Ended earlyNCT05694741
What this trial is testing

Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

Who this might be right for
Type 2 Diabetes
AstraZeneca 31
Not applicableUnknownNCT06182852
What this trial is testing

The Effect of GLP-1 Receptor Agonist on Bone Metabolism in Patients With Diabetes Mellitus

Who this might be right for
Diabete Type 2Bone Metabolism
Nanjing First Hospital, Nanjing Medical University 330
Not applicableNot Yet RecruitingNCT07340112
What this trial is testing

Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia

Who this might be right for
Peripheral Arterial Disease (PAD)Claudication, IntermittentChronic Limb-Threatening Ischemia
University Hospital, Strasbourg, France 50
Next Page